In a significant development, SUDA Pharmaceuticals Limited (ASX:SUD) has reported preliminary results from a pharmacokinetic study that assessed novel mouth spray formulations of Anagrelide.
The study results involving five animals indicate that one of the formulations was able to improve the bioavailability of Anagrelide while lowering the exposure to a cardio stimulatory metabolite. It is imperative to note that these results support the Company’s hypothesis that mouth spray formulation of Anagrelide can be more safely administered to cancer patients, possibly leading to fewer cardiovascular side-effects.
Prior to completing further preclinical testing, SUDA will continue optimising Anagrelide formulation to meet pharma-grade oral spray product requirements.
SUD is trading higher at $0.046, with a rise of ~7% as at 11:33 AM AEST.